Ruxolitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary Myelofibrosis.

Conditions

Ruxolitinib — DRUG
Ruxolitinib is a medication that blocks certain proteins called tyrosine kinases. Specifically, it blocks tyrosine kinases called JAK2. The JAK2 pathway is over active in the disease, acute myeloid leukemia.

This research study is studying a drug called Ruxolitinib as a possible treatment for Myelofibrosis.

Experimental: Ruxolitinib Eligible pre-HSCT
* Ruxolitinib will be taken orally at a fixed dose twice every day * Dosing will be continuous, with a new cycle scheduled to start every 28 days. * There will be no break in dosing between cycles * Ruxolitinib can be administered with or without food.
Experimental: Ruxolitinib Not Eligible pre-HSCT
* Ruxolitinib will be taken orally at a fixed dose twice every day after transplant * Dosing will be continuous, with a new cycle scheduled to start every 28 days. * There will be no break in dosing between cycles * Ruxolitinib can be administered with or without food.

GVHD free and relapse free survival at 1 year [ Time Frame: 1 year ]

Facility	City	State	ZIP	Site coordinators
Massachusetts General Hospital	Boston	Massachusetts	02214	-
Washington University	St Louis	Missouri	63130	-
Memorial Sloan Kettering Cancer Center	New York	New York	10065	-
The Ohio State University Wexner Medical Center	Columbus	Ohio	43210	-
Vanderbilt University	Nashville	Tennessee	37235	-

By research site